Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2025)
Monopar Therapeutics' (MNPR) quarterly Profit After Tax came in at -$3.4 million in Q3 2025, down 163.62% year-on-year from $5.4 million in Q3 2024, and down 40.11% quarter-over-quarter from -$2.5 million in Q2 2025.
Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Profit After Tax across 9 years of filings, most recently posting -$3.4 million for Q3 2025.
- Profit After Tax for Q3 2025 came in at -$3.4 million, down 163.62% year-over-year; the trailing twelve-month figure through Sep 2025 was -$9.8 million (down 48.47% YoY), and the FY2024 annual result was -$15.6 million, down 85.94% from the prior year.
- Profit After Tax came in at -$3.4 million for Q3 2025 at Monopar Therapeutics, down from -$2.5 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$1.3 million in Q3 2024 to a low of -$3.4 million in Q3 2025.
- The 5-year median for Profit After Tax is -$2.4 million (2023), against an average of -$2.3 million.
- Across the five-year window, Profit After Tax soared 33.26% in 2024 and plunged 163.62% in 2025, its largest moves.
- Monopar Therapeutics' Profit After Tax stood at -$2.7 million in 2021, then decreased by 8.05% to -$2.9 million in 2022, then soared by 32.54% to -$2.0 million in 2023, then jumped by 33.26% to -$1.3 million in 2024, then tumbled by 163.62% to -$3.4 million in 2025.
- The last three Profit After Tax figures came in at -$3.4 million (Q3 2025), -$2.5 million (Q2 2025), and -$2.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.74 Mn |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.64 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.20 Mn |
| Mar 31, 2023 | -2.43 Mn |
| Dec 31, 2022 | -2.90 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.08 Mn |
| Mar 31, 2021 | -1.88 Mn |
| Dec 31, 2020 | -2.13 Mn |
| Sep 30, 2020 | -1.64 Mn |
| Jun 30, 2020 | -1.45 Mn |